Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR), today announced that the Company’s Investigational New Drug application (IND) for idiopathic pulmonary fibrosis (IPF) has successfully passed the FDA’s 30-day review process and has been allowed to go into effect. A Phase II, 60-patient study to test low dose oral interferon as a treatment of chronic cough in IPF patients is on target to launch in the fourth quarter of 2006.
